Results 21 to 30 of about 1,458,916 (304)
PLoS ONE, 2021 BackgroundProton pump inhibitors (PPIs) are known to reduce the risk of upper gastrointestinal bleeding in patients on oral anticoagulants, and patients are increasingly on oral anticoagulants and PPI co-therapy.
Hyun-Jung Lee +7 more
doaj +1 more source
Effects of oral anticoagulants on bone health (systematic literature review)
Bolʹ, Sustavy, Pozvonočnik, 2023 Background. Osteoporosis is actually today's problem, as it affects the quality and length of life, and increases the risk of fragility fractures, which leads to significant medical, social, and economic problems.
H.V. Mostbauer +4 more
doaj +1 more source
The new oral anticoagulants [PDF]
Blood, 2010 Abstract Although their first application in clinical practice occurred in the 1940s, vitamin K antagonists remain the only form of oral anticoagulant medication approved for long-term use. Although the available vitamin K antagonists are highly effective for the prevention and/or treatment of most thrombotic disease, the significant ...
David, Garcia +2 more
openaire +5 more sources
Oral anticoagulants in the elderly [PDF]
British Journal of Haematology, 2003 Summary. Over a 1‐year period, 34 998 prothrombin time tests were performed on 2379 patients aged 40–89 years with a recommended target International Normalized Ratio (INR) value of 2·5. At least one INR value of ≥ 5 was found in 507/2379 patients (21·3%).
Paul, Froom, Ehud, Miron, Mira, Barak
openaire +2 more sources
Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review
Рациональная фармакотерапия в кардиологии, 2022 The last decade has dramatically changed the strategy of anticoagulant therapy in patients with atrial fibrillation. Direct oral anticoagulants have replaced vitamin K antagonists: either direct thrombin blockers (dabigatran) or factor IIa blockers ...
B. A. Tatarsky, N. V. Kazennova
doaj +1 more source
Российский кардиологический журнал, 2019 Patients with atrial fibrillation have a high risk of developing stroke and death, which requires constant anticoagulant support. In this regard, the physician faces the difficult task of selecting the appropriate oral anticoagulant for patient with ...
N. N. Kryukov +3 more
doaj +1 more source
Безопасность и риск фармакотерапии, 2019 New oral anticoagulants are effective for the prevention of thromboembolic complications in patients with atrial fibrillation, or after orthopedic surgery.
A. P. Pereverzev +3 more
doaj +1 more source
Oral anticoagulants: Optimizing venous thromboembolism management
Journal of Applied Hematology, 2019 A decade ago, oral anticoagulants were limited to Vitamin K antagonists, i.e., warfarin. Since 2010, the US Food and Drug Administration has approved several non-Vitamin K oral anticoagulants: dabigatran is a direct thrombin inhibitor, while apixaban ...
Fahad A S. Aleidan
doaj +1 more source
The new oral anticoagulants [PDF]
Clinical Medicine, 2011 Anticoagulants have been used for over 70 years for prevention and treatment of potentially fatal thromboembolic events. Heparins and vitamin K antagonists have been the mainstay of treatment and, although effective if managed properly, also have significant drawbacks. Unfractionated heparins (UFH)
Breen, K. A., Hunt, B. J.
openaire +3 more sources
Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]
, 2014 Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
Camm, AJ +3 more
core +1 more source